



British Heart
Foundation

Research Grant Awards

2025-2026



Contents

Introduction	3
BHF Chairholders and Research Professor	4
Awards made during the year: 1 April 2025 - 31 March 2026	7
Fellowships	7
Strategic Initiatives	15
Infrastructure Grant	15
Special Project Grant	15
Programme Grants	16
New Horizons Grant	17
International Awards	17
Clinical Study Grants	18
Translational Awards	18
Translational Pump Priming Awards	19
Project Grants	20

Introduction

In the year April 2025 to March 2026 British Heart Foundation (BHF) awarded grants totalling £103.4 million* for research into the causes, prevention, diagnosis and treatment of cardiovascular disease.

BHF has five research grant committees, each of which meets up to four times a year. The members of each committee are experts in various aspects of basic and clinical cardiovascular research. Applications are sent to independent reviewers before being assessed by the committee. Judgements are made on factors such as scientific merit, relevance to cardiovascular disease, timeliness, relationship to other work in the field, and value for money. Applicants for Translational Awards, and shortlisted applicants for Research Professorships and some Fellowship schemes, are interviewed.

The Chairs and Programme Grants Committee awarded £44.8 million. This included £1.3 million for a new BHF Research Professorship to Professor G McCann at University of Leicester, £5 million to University of Glasgow for The BHF

Scottish National Cardiovascular Research Network, and £10 million for the Data Science Centre for continued funding of infrastructure and services.

There were 25 awarded Chairs and Research Professorships on 31 March 2026. These receive a site visit after five years to assess past research performance, future plans, and proposed expenditure for renewal if eligible. The visiting team includes internationally renowned scientists.

The Clinical Studies Committee supports clinical trials of treatments, diagnostics and other interventions and certain observational studies of specific patient groups. The Committee awarded £3.1 million to five applications.

The Translational Awards Committee awarded £0.4 million** to three applications for the development of cardiovascular research through early pre-clinical milestones, with the aim of advancing the research to be attractive for larger follow-on investment, and £0.4 million to 10 Pump Priming applications.

The Fellowships Committee awarded £23.9 million to 70 applications***, and approved seven new 4-year Multidisciplinary PhD Studentship Programmes which will appoint students from the 2026/27 academic year.

The Project Grants Committee awarded £17.1 million to 55 applications.

The pages that follow list BHF Chairs and Research Professorships, and new awards made during the year by each of the Committees. Full details of all types of awards offered, and the application process, can be found on BHF's website: bhf.org.uk/research

Notes

* This figure includes supplements made to existing grants, as well as \$6.7 million towards Wellcome Leap (awarded by the Executive Committee), £984,214 towards 48 Open Access Block Grants, and £12,377 towards six Small Meetings which are not listed in the following pages. It excludes awards made by Healthcare Innovation.

** This figure includes only the expected payments to the next milestone for grants which are conditional upon the successful achievement of project milestones.

*** One award totalling £366,727.58 included in this figure was declined and is not listed in the following pages.

BHF Chairholders and Research Professor

Chairholders

Listed alphabetically by institution

Imperial College London

The Chair of Cardiovascular Medicine

Held by: Professor B Casadei

Major interest: Redox signalling in cardiovascular disease, particularly atrial fibrillation.

Imperial College London

The Chair of Cardiovascular Science

Held by: Professor C Emanueli

Major interest: Growth and repair of adult blood vessels: roles of stem cells and angiogenic factors.

Imperial College London

The Chair of Cardiovascular Proteomics

Held by: Professor M Mayr

Major interest: Novel methods to detect and measure biomarkers of cardiovascular risk.

Imperial College London

The Chair of Cardiovascular AI

Held by: Professor D O'Regan

Major interest: Understanding cardiovascular risk and disease progression through AI analysis of cardiac imaging and other data sets.

King's College London

The Chair of Molecular Cardiology

Held by: Professor M Gautel

Major interest: Cellular and molecular biology of the contractile proteins in heart muscle.

King's College London

The Chair of Cardiology

Held by: Professor A Shah

Major interest: Cellular and molecular biology of production of reactive oxygen species in the cardiovascular system and their roles in atherosclerosis, cardiac hypertrophy and heart failure.

Queen Mary, University of London

The Chair of Cardiovascular Immunology

Held by: Professor F Marelli-Berg

Major interest: Control of T lymphocyte homing to the heart in rejection, autoimmunity and inflammation.

University of Bristol

The Chair of Congenital Heart Surgery

Held by: Professor M Caputo

Major interest: Cardiac surgical research, particularly in congenital heart disease.

University of Bristol

The Chair of Cardiovascular Science and Clinical Epidemiology

Held by: Professor D Lawlor

Major interest: Population health: links between ethnicity, genetics and health during pregnancy on the long-term cardiovascular health of mothers and children.

University of Cambridge

The Chair of Cardiovascular Sciences

Held by: Professor M Bennett

Major interest: Molecular mechanisms controlling smooth muscle cell proliferation, ageing and death in atherosclerosis.

University of Cambridge

The Chair of Epidemiology and Medicine

Held by: Professor J Danesh

Major interests: Cardiovascular epidemiology; large-scale studies of genetic and biochemical factors.

University of Cambridge

The Chair of Cardiovascular Medicine

Held by: Professor Z Mallat

Major interest: Cellular and molecular control of immune processes in atherosclerosis and vascular inflammation.

University of Edinburgh

The Chair of Translational Cardiovascular Sciences

Held by: Professor A Baker

Major interest: Gene and cell-based therapies to combat vascular disease.

University of Edinburgh

The BHF Chair of Cardiology

Held by: Professor N Mills

Major interest: Using digital healthcare data to learn about heart disease and its consequences and cardiovascular diagnostics.

University of Edinburgh

The Duke of Edinburgh Chair of Cardiology

Held by: Professor D Newby

Major interest: Experimental cardiovascular medicine, including studies of air pollution as a risk factor for cardiovascular disease.

University of Leeds

The Chair of Cardiovascular and Diabetes Research

Held by: Professor M Kearney

Major interest: Mechanisms by which insulin resistance and diabetes exacerbate atherosclerosis.

University of Leeds

The Chair of Cardiovascular Imaging

Held by: Professor S Plein

Major interest: Innovative cardiac magnetic resonance imaging for patient diagnosis and assessment.

University of Leicester

The Chair of Vascular Surgery

Held by: Professor M Bown

Major interests: Causes of, and screening for, aortic abdominal aneurysms, and treatments for peripheral arterial disease.

University of Leicester

The Chair of Cardiac Surgery

Held by: Professor G Murphy

Major interest: Strategies to reduce distal organ injury occurring during cardiac surgery.

University of Manchester

The Chair of Cardiology

Held by: Professor B Keavney

Major interest: Genetics of heart disease.

University of Oxford

The BHF Chair of Cardiovascular Medicine

Held by: Professor C Antoniades

Major interest: How fat in the body and surrounding arteries communicates with the heart and blood vessels, leading to heart attacks and strokes.

University of Oxford

The Field Marshal Earl Alexander Chair of Cardiovascular Medicine

Held by: Professor K Channon

Major interests: Redox signalling in atherosclerosis; using genetics and genomics to discover novel molecular pathways in atherosclerosis.

University of Oxford

The Chair of Regenerative Medicine

Held by: Professor P Riley

Major interest: Developmental biology of the heart and its applications to cardiac regenerative medicine.

University of Oxford

The Chair of Cardiovascular Medicine

Held by: Professor H Watkins

Major interests: Genetics and underlying molecular mechanisms in hypertrophic cardiomyopathy; genetics of coronary artery disease.

Research Professor

University of Leicester

The Research Professor of Cardiology

Held by: Professor G McCann from 1 April 2026

Major interests: Use of cardiac imaging, in particular MRI, to better understand and manage patients with or at high risk of developing cardiovascular diseases.

Awards made during the year

1 April 2025 - 31 March 2026

Fellowships

Listed alphabetically by institution

Non-clinical Fellowships

Senior Basic Science Research Fellowships

FS/SBSRF/25/31070	Dr	A	D'Souza	Imperial College London	Galectin-3 inhibition to restore atrioventricular node function in heart failure. <i>60 months</i>	£1,176,539.00
FS/SBSRF/25/31075	Prof	P	Longhi	Queen Mary, University of London	Lipid-autoreactive T cells as a biomarker and therapeutic target in coronary artery disease. <i>60 months</i>	£1,037,400.98

Intermediate Basic Science Research Fellowships

FS/IBSRF/26/25340	Dr	S	El-Mansi	Queen Mary, University of London	Endothelial Piezo1: a molecular driver of deep vein thrombosis. <i>60 months</i>	£863,291.66
FS/IBSRF/26/25317	Dr	S	Montague	University of Birmingham	Stop the clot: targeting platelets and neutrophils in Platelet Factor 4 associated Immune Thrombocytopenia and Thrombosis (PITT). <i>60 months</i>	£740,346.35
FS/IBSRF/25/25323	Dr	N	North	University of Leeds	Harnessing endothelial-derived paracrine signals to remodel adipose tissue and improve cardiometabolic health. <i>60 months</i>	£798,983.55
FS/IBSRF/25/25282	Dr	N	Stathopoulou	University of Oxford	Epigenetic regulation of cardiac development and congenital heart disease. <i>60 months</i>	£919,738.06

Career Re-entry Research Fellowships

FS/CRERF/DJT/26/22507	Dr	O	Ojo	University of Bristol	Joint BHF/Daphne Jackson Fellowship: Investigating G Protein-Coupled Receptor (GPCR) function in platelets and vascular smooth muscle cells to preserve cardiovascular integrity. <i>36 months</i>	£199,942.26
FS/CRERF/DJT/26/22505	Dr	K	Onions	University of Bristol	Joint BHF/Daphne Jackson Fellowship: Compositional analysis of the glomerular glycocalyx: identifying disease-related damage and therapeutic targets to restore endothelial function. <i>36 months</i>	£199,745.39

Immediate Postdoctoral Basic Science Research Fellowships

FS/IPBSRF/26/27237	Dr	S	Neves Silva	King's College London	Novel approachEs for explOring Placental, fetAl and mateRnal vascular adaptations in Disease (LEOPARD). <i>48 months</i>	£395,086.58
FS/IPBSRF/26/27224	Dr	R	Su	University College London	Targeting Sdc2/ VISTA axis in pulmonary arterial hypertension. <i>48 months</i>	£422,380.09
FS/IPBSRF/25/27173	Dr	D	Turkmen	University of Exeter	Stay on track: improving cardiovascular medication adherence for better cardiovascular outcomes. <i>48 months</i>	£279,772.90
FS/IPBSRF/25/27203	Dr	F	Felix-Ilemhenbho	University of Sheffield	Development of a block-and-replace gene therapy for CADASIL: targeting mutant NOTCH3 to restore cerebrovascular function. <i>48 months</i>	£453,061.00

3-year PhD Studentships

FS/PhD/25/29641	Mr	A	Bera	Cardiff University	Investigation of the anti-atherogenic actions of pinolenic acid together with the underlying molecular mechanisms using <i>in vitro</i> and <i>in vivo</i> model systems. <i>36 months</i>	£128,579.15
FS/PhD/25/29787	Ms	W	Feng	City St George's, University of London	Molecular mechanisms of sex differences in mitochondrial cardiomyopathy. <i>36 months</i>	£131,365.40
FS/PhD/26/29867	Miss	C	Parsons	Glasgow Caledonian University	Remodelling of cAMP signalling and E-C coupling in heart failure with preserved ejection fraction (HFpEF). <i>36 months</i>	£134,662.50
FS/PhD/26/29806	Mr	M	Khan	Imperial College London	Engineering stable microvascular networks from hiPSC vascular organoids via angiopoietin signalling for regenerative therapy in peripheral arterial disease. <i>36 months</i>	£165,766.40
FS/PhD/25/29746	Miss	V	Rapson	King's College London	Novel redox-based CDK4 inhibitors for disease modification in pulmonary hypertension. <i>36 months</i>	£148,541.05
FS/PhD/25/29744	Miss	I	Chaudhry	Newcastle University	Understanding inequalities in access to care in adult congenital heart disease (ACHD) to improve models of surveillance for underserved groups. <i>36 months</i>	£127,780.38
FS/PhD/26/29836	Ms	D	Smith	Queen Mary, University of London	Investigating soluble Neuropilin-1 as a biomarker for cardiovascular disease and its role in endothelial activation. <i>36 months</i>	£142,381.40
FS/PhD/26/29818	Miss	I	Buchanan	University of Birmingham	Harnessing PEPITEM to disrupt inflammatory networks in type 2 diabetes and vascular disease. <i>36 months</i>	£148,995.64
FS/PhD/25/29778	Miss	S	Ghanbari Basteh Deimi	University of Birmingham	Neutrophil S100 proteins synergistically fuel a hyperinflammatory platelet subset driving immunothrombosis. <i>36 months</i>	£143,761.64
FS/PhD/26/29855	Mr	M	Curtis	University of Bristol	<i>Ex vivo</i> live imaging of macrophage phagocytosis to assess the mechanisms necessary for collagen scar removal during cardiac regeneration. <i>36 months</i>	£133,726.84
FS/PhD/25/29771	Mr	T	Osborne	University of Bristol	AI-assisted unbiased docking as a tool for prediction of hERG channel block liability. <i>36 months</i>	£114,364.50

FS/PhD/26/29821	Ms	L	Jay	University of East Anglia	Decoding the role of YAP1 in haematoendothelial progenitor mechanobiology during early cardiovascular development. <i>36 months</i>	£134,290.07
FS/PhD/25/29676	Ms	P	Philpott	University of Edinburgh	Defining the role of the centriolar protein trichoplein (TCHP) in brain endothelial cells for targeting vascular dementia. <i>36 months</i>	£126,393.18
FS/PhD/26/29866	Ms	S	Kiely	University of Exeter	Using genetics to understand the impact of pregnancy on later maternal cardiovascular health. <i>36 months</i>	£127,921.50
FS/PhD/26/29846	Ms	T	Johnson	University of Hull	Understanding the mechanistic basis of arginine methylation in regulating the critical platelet integrin $\alpha_{IIb}\beta_3$. <i>36 months</i>	£133,279.79
FS/PhD/26/29871	Ms	Y	Qui	University of Hull	Defining the mechanism platelet COX-1 inhibition by indoxyl sulfate: implications for anti-platelet therapy in high-risk patients. <i>36 months</i>	£134,090.50
FS/PhD/25/29742	Ms	F	Steinke	University of Hull	Phosphofructokinase FB3: a novel regulator of platelet function. <i>36 months</i>	£129,860.90
FS/PhD/25/29749	Mr	C	Scanlan	University of Leeds	Does LRG1 protect against metabolic dysfunction in obesity by maintaining vascular phenotype and function in white adipose tissue? <i>36 months</i>	£129,805.27
FS/PhD/26/29803	Miss	A	Landers	University of Nottingham	Structural investigation of SLC44A2 domain ED1: a novel target for anti-thrombotic therapy. <i>36 months</i>	£134,414.93
FS/PhD/26/29826	Mr	N	Ahmed	University of Oxford	AI-based approaches for cardiometabolic risk prediction and novel hypotheses generation in women with reproductive endocrine disorders. <i>36 months</i>	£150,646.50
FS/PhD/25/29700	Ms	Z	Shi	University of Oxford	Electrochemical characterisation of catecholaminergic signalling in Dbh ⁺ cardiomyocytes and its physiological role in murine heart. <i>36 months</i>	£147,404.90
FS/PhD/25/29623	Ms	S	Sigal	University of Oxford	Molecular analysis of venous endothelial cell fate and function. <i>36 months</i>	£139,324.14
FS/PhD/25/29714	Ms	M	Clements	University of Sheffield	Age as a major risk factor for cardiovascular events: rescue of dysregulated MYC in macrophages by dietary supplement fisetin. <i>36 months</i>	£126,443.90
FS/PhD/26/29830	Ms	A	Crichton	University of St Andrews	The role of MG23 in regulating vascular contractility in hypertension. <i>36 months</i>	£134,419.24

Clinical Fellowships

Senior Clinical Research Fellowship

FS/SCRF/25/32043	Dr	J	Tarkin	University of Cambridge	Imaging the effects of interleukin-6R blockade on high-risk coronary Atherosclerosis (IDEA) study. 60 months	£1,452,521.00
------------------	----	---	--------	-------------------------	--	---------------

Intermediate Clinical Research Fellowship

FS/ICRF/25/26134	Dr	K	Lee	University of Edinburgh	AI to inform differential diagnosis in acute cardiac care. 60 months	£1,398,705.56
------------------	----	---	-----	-------------------------	--	---------------

Consultant Research Awards

FS/CRA/25/23080	Dr	D	Austin	Newcastle University	Addressing research challenges in cardio-oncology: a patient-level meta-analysis and multicentre registry. 48 months	£406,224.00
FS/CRA/25/23083	Dr	D	Knight	University College London	Identifying and understanding distinct cardiovascular phenotypes in systemic sclerosis. 60 months	£541,820.11
FS/CRA/25/23053	Dr	S	Agarwal	University of Cambridge	Predicting Recovery in acute Ischaemic Stroke using Machine learning (PRISM). 60 months	£433,666.09
FS/CRA/25/23108	Dr	J	Ormerod	University of Oxford	The diagnostic utility of the long burst long pause short-coupled protocol in calcium release deficiency syndrome. 60 months	£259,964.16

Clinical Research Training Fellowships

FS/CRTF/25/24823	Dr	R	Sritharan	City St George's, University of London	Generalised lymphatic dysplasia: understanding the aetiology and natural history to improve management. <i>36 months</i>	£353,194.07
FS/CRTF/25/24834	Dr	H	Aggour	Imperial College London	Evaluating the reproducibility and robustness of AI-ECG predictions. <i>24 months</i>	£205,652.00
FS/CRTF/25/24752	Dr	A	El-Medany	Imperial College London	Prospective evaluation of AI-enhanced electrocardiography for diagnosis of structural heart disease. <i>24 months</i>	£257,414.00
FS/CRTF/25/24802	Dr	N	Kaza	Imperial College London	Optimising pacing therapies for ventricular arrhythmia using implantable devices. <i>36 months</i>	£386,188.79
FS/CRTF/26/24874	Dr	S	Misra	Imperial College London	The impact of the coronary sinus reducer on myocardial perfusion and symptoms in patients with non-obstructive hypertrophic cardiomyopathy. <i>36 months</i>	£376,371.50
FS/CRTF/25/24768	Dr	J	Samways	Imperial College London	Arrhythmia risk in conduction system pacing. <i>36 months</i>	£390,432.41
FS/CRTF/25/24771	Dr	A	Stevenson	Imperial College London	Realtime AI-led exercise cardiac magnetic resonance to discriminate between fitness-driven changes and early pathological remodelling. <i>36 months</i>	£382,530.14
FS/CRTF/25/24728	Dr	M	Klis	King's College London	Atrial electrophysiology in hypertrophic cardiomyopathy. <i>28 months</i>	£292,606.23
FS/CRTF/26/24862	Dr	A	Liew	King's College London	Left bundle branch area pacing versus right ventricular leadless pacing: acute effects on biventricular and tricuspid valve function. <i>36 months</i>	£403,228.21
FS/CRTF/25/24841	Dr	B	McDonagh	King's College London	PREDicting functional and clinical outcomes following transcatheter trICuspid valve intervention for severe Tricuspid Regurgitation (PREDICT-TR). <i>36 months</i>	£372,975.18
FS/CRTF/25/24845	Dr	A	Khan	Queen Mary, University of London	Next generation coronary plaque characterisation and computation of flow patterns: photon counting computed tomography coronary angiography versus state-of-the-art multimodality intravascular imaging. <i>36 months</i>	£327,375.31

FS/CRTF/25/24807	Dr	A	Shetye	University College London	Left ventricular reverse remodelling after valve replacement in aortic valve disease: microstructural insights from diffusion tensor imaging. <i>36 months</i>	£424,781.37
FS/CRTF/26/24889	Dr	H	Zaw	University College London	Defining the frequency and identifying mechanisms of lead failure in pacemakers and defibrillators using population health records and intracardiac electrograms. <i>30 months</i>	£325,793.08
FS/CRTF/25/24837	Dr	E	Hassan	University of Birmingham	Does combination of antioxidant with tyrosine kinase inhibitors prevent sickle cell disease-associated thrombo-inflammation and vascular occlusion? <i>28 months</i>	£269,261.11
FS/CRTF/26/24898	Dr	F	Mouy	University of Bristol	Targeting purinergic signalling to improve the control of breathing in HFpEF. <i>36 months</i>	£378,590.00
FS/CRTF/25/24788	Dr	I	Lyell	University of Edinburgh	Understanding and reducing inequalities in the assessment of risk and prevention of cardiovascular disease. <i>45 months</i>	£315,451.75
FS/CRTF/26/24818	Dr	M	Haris	University of Leeds	PREVENTion of Atrial Fibrillation in high-risk individuals by cardio-renal-metabolic pharmacological intervention (PREVENT-AF): randomised feasibility study. <i>36 months</i>	£417,061.98
FS/CRTF/26/24865	Dr	J	Chiong	University of Liverpool	DYNAMITE VT – ‘Dynamic Voltage Mapping’ to personalise the ventricular tachycardia substrate. <i>36 months</i>	£280,116.00
FS/CRTF/25/24786	Dr	S	Ma	University of Oxford	Exploring the role of interleukin-11 in patients with atrial fibrillation. <i>28 months</i>	£275,109.58
FS/CRTF/25/24808	Dr	J	Solano Velasquez	University of Oxford	Improving the diagnosis and treatment of exercise intolerance using combined cardiac magnetic resonance and cardiopulmonary exercise testing. <i>36 months</i>	£404,575.25
FS/CRTF/25/24757	Dr	P	Tang	University of Oxford	Investigating left atrial blood flow and endothelial function in atrial cardiomyopathy to identify new opportunities for prevention of stroke and atrial fibrillation. <i>36 months</i>	£390,202.85

Career Development Research Fellowship (for Nurses and Healthcare Professionals)

FS/CDRF/26/21096	Dr	R	McNally	King's College London	Tackling the silent killer: pharmacist-led personalised hypertension management. <i>36 months</i>	£373,361.77
------------------	----	---	---------	-----------------------	---	-------------

MBPhD Studentships

FS/MBPhD/25/28044	Mr	A	Birdi	Imperial College London	Utilising AI on serial electrocardiogram recordings for personalised clinical risk prediction. <i>36 months</i>	£122,920.80
FS/MBPhD/26/28054	Miss	R	Lam	Queen Mary, University of London	The mechanism and impact of senescence on endothelial storage organelle release and function. <i>36 months</i>	£140,644.40
FS/MBPhD/26/28055	Ms	D	Odunsi	Queen Mary, University of London	Epigenomic and cellular analyses of candidate modifier <i>loci</i> in hypertrophic cardiomyopathy. <i>36 months</i>	£145,159.40

Research Training Fellowship (for Nurses and Allied Health Professionals)

FS/RTF/26/30099	Mrs	J	Richardson	University of Glasgow	Exploring green space interventions to improve recovery and wellbeing after heart surgery. <i>36 months</i>	£290,091.32
-----------------	-----	---	------------	-----------------------	---	-------------

Travel Fellowship

FS/TF/26/33045	Dr	O	Murray	University of Manchester	Improving prognostic models by utilising routine clinical imaging in intracerebral haemorrhage. <i>12 months</i>	£5,600.00
----------------	----	---	--------	--------------------------	--	-----------

Strategic Initiatives

Listed alphabetically by institution

SI/F/26/21170029				Academy of Medical Sciences	Academy of Medical Sciences Starter Grants for Clinical Lecturers (renewal). <i>48 months</i>	£1,067,000.00
SI/F/26/21170028				Academy of Medical Sciences	Academy of Medical Sciences Springboard Awards for Biomedical Researchers (renewal). <i>36 months</i>	£843,000.00
SI/F/26/21170023				British Atherosclerosis Society	Support for the BAS/BSCR basic science track of the 2026 British Cardiovascular Society Conference. <i>12 months</i>	£30,605.00
SI/F/26/21170024				British Cardiovascular Society	Support for the 2026 British Cardiovascular Society Conference. <i>12 months</i>	£107,279.09
SI/F/25/21170022				Health Data Research UK	BHF Data Science Centre (renewal): Cardiovascular Research Data Infrastructure and Services in the UK. <i>60 months</i>	£10,000,000.00
SI/F/26/21170025	Prof	R	Myles	University of Glasgow	The BHF Scottish National Cardiovascular Research Network (Scottish NCRN). <i>60 months</i>	£4,994,696.13
SI/F/26/21170027				Wellcome Trust	Europe PubMed Central (renewal). <i>60 months</i>	£209,942.49

Infrastructure Grant

IG/F/25/50016	Prof	G	Richardson	Newcastle University	High-resolution pre-clinical ultrasound imaging system. <i>12 months</i>	£137,282.78
---------------	------	---	------------	----------------------	--	-------------

Special Project Grant

SP/F/25/150090	Prof	M	Williams	University of Edinburgh	Coronary artery disease initiation or progression in the long term: the SCOT-HEART evolution study. <i>36 months</i>	£1,596,145.00
----------------	------	---	----------	-------------------------	--	---------------

Programme Grants

Listed alphabetically by institution

RG/F/25/110167	Prof	A	Lawrie	Imperial College London	Capture of real-world data from smartphones and wearables linked to healthcare records to support early diagnosis and future management of pulmonary arterial hypertension (MHC-PAH). <i>60 months</i>	£2,539,048.81
RG/F/25/110163	Prof	M	Bishop	King's College London	Localisation of ventricular tachycardia by advanced computational algorithms: fulfilling the potential of clinical translation. <i>60 months</i>	£1,285,430.95
RG/F/25/110175	Prof	P	Evans	Queen Mary, University of London	Integrating mechanobiology with fluid dynamics to predict accelerated coronary artery disease. <i>60 months</i>	£1,047,349.25
RG/F/25/110156	Prof	T	Iskratsch	Queen Mary, University of London	Role of the mechano-lipid metabolic signalling axis in cardiovascular disease. <i>60 months</i>	£1,143,872.80
RG/F/25/110165	Prof	F	Marelli-Berg	Queen Mary, University of London	Harnessing T-cell cardiotropism to define and target adaptive immunity in cardiac inflammatory diseases. <i>60 months</i>	£1,422,561.21
RG/F/26/110201	Prof	M	Fontana	University College London	Pathophysiology, deep phenotyping and treatment of cardiac ATTR amyloidosis: experimental modelling to disease reversal. <i>60 months</i>	£2,350,594.50
RG/F/25/110168	Prof	M	Hamer	University College London	Optimisation of physical behaviour for CVD prevention through creative use of wearable data and technologies. <i>60 months</i>	£1,902,876.79
RG/F/25/110148	Prof	P	Lambiase	University College London	Targeting the heart-brain neuroaxis for the treatment of cardiac arrhythmias. <i>60 months</i>	£1,444,857.31
RG/F/26/110184	Prof	M	Delibegovic	University of Aberdeen	Delineating macrophage cholesterol homeostasis pathways regulated by Protein Tyrosine Phosphatase 1B (PTP1B) signalling in atherosclerosis. <i>60 months</i>	£1,124,038.37

RG/F/25/110183	Prof	T	Guzik	University of Edinburgh	Identification of brain-immune circuits that control aortic aneurysms. <i>60 months</i>	£2,436,686.38
RG/F/25/110169	Prof	N	Mills	University of Edinburgh	Implementing a new clinical classification of myocardial infarction. <i>60 months</i>	£2,527,216.10
RG/F/25/110173	Dr	C	Lygate	University of Glasgow	Therapeutic manipulation of creatine and homoarginine for heart disease. <i>60 months</i>	£1,293,310.64
RG/F/26/110190	Prof	E	Tzima	University of Oxford	Role of Plexin D1 in endothelial responses to fluid shear stress. <i>60 months</i>	£1,330,407.30

New Horizons Grant

NH/F/25/70015	Assoc Prof	J	Armstrong	University of Bristol	Engineering mechanocompetent conduits with growth potential for right ventricular outflow tract reconstruction. <i>36 months</i>	£299,522.74
---------------	------------	---	-----------	-----------------------	--	-------------

International Awards

Listed alphabetically by institution

IA/F/25/275200	Dr	F	Ng	Imperial College London	Ventricular Arrhythmia Mechanisms and Prediction through Multi-Domain integration (VAMP-MD). (Joint funding with the Dutch Heart Foundation and the Lefoulon-Delalande Foundation). <i>48 months</i>	£400,610.00
IA/F/25/275166	Dr	N	Akbar	University of Oxford	The impact of Aging on Interorgan Dysfunction following acute Myocardial Infarction (AID-MI). (Joint funding with the German Centre for Cardiovascular Research and the Lefoulon-Delalande Foundation). <i>36 months</i>	£497,502.19
IA/F/25/275189	Dr	L	Heather	University of Oxford	SHEA-META: Sex-specific HEart-Adipose communication driving METAbolic dysfunction in diabetic cardiomyopathy. (Joint funding with the Dutch Heart Foundation and the Lefoulon-Delalande Foundation). <i>48 months</i>	£492,943.10

Clinical Study Grants

Listed alphabetically by institution

CS/F/25/190104	Prof	E	Akowuah	Newcastle University	The Repeat intervention for dEteriorated surgical bioProsthEtic AorTic valves (REPEAT) Trial: a multi-centre randomised trial comparing redo surgical aortic valve replacement to valve-in-valve transcatheter aortic valve replacement. <i>90 months</i>	£843,156.86
CS/F/25/190102	Prof	D	Werring	University College London	The safety and efficacy of intravenous thrombolysis in patients with ischaemic stroke and recent ingestion of direct oral anticoagulants – the DOAC International Thrombolysis (DO-IT) Trial. <i>36 months</i>	£319,691.23
CS/F/25/190105	Prof	M	Dewey	University of Cambridge	Invasive or Non-invasive Coronary angiography in stable patients with High clinical likelihood of coronary ARtery disease accordinG to European guidelines (INCHARGE). <i>72 months</i>	£543,656.43
CS/F/25/190092	Prof	D	Blackman	University of Leeds	TraNscatheter Aortic Valve Implantation vs surGical AorTic valvE replacement in patients with Bicuspid aortic valve stenosis (NAVIGATE Bicuspid). <i>96 months</i>	£760,669.86
CS/F/25/190075	Prof	A	Ng	University of Leicester	Early atrial fibrillation Ablation for STroke prevention in patients with high comorbidity burden. The EAST High-AFNET 11 Trial – UK arm (EASThigh-UK). <i>60 months</i>	£599,474.63

Translational Awards

Listed alphabetically by institution

TA/F/25/210060	Dr	C	von Stempel	University College London	Photoacoustic tomography in the assessment of microvasculature in peripheral arterial disease. <i>36 months</i>	£663,459.02
TA/F/25/210061	Prof	H	Markus	University of Cambridge	HDAC9 inhibition to treat stroke and atherosclerotic cardiovascular disease. <i>36 months</i>	£466,096.11
TA/F/25/210059	Prof	S	Forbes	University of Edinburgh	Development of the e-cardiac scanner: a bench-top device to rapidly screen new drugs for drug discovery and cardiac safety. <i>36 months</i>	£713,754.09

Translational Pump Priming Awards

Listed alphabetically by institution

TA/PPA/25/215027	Dr	N	MacQuaide	Glasgow Caledonian University	Pre-clinical heart failure therapeutic peptide testing in human iPSC cardiomyocytes. <i>8 months</i>	£48,145.00
TA/PPA/25/215030	Dr	E	Corsiero	Queen Mary, University of London	Cardiac fibrosis inhibition by cMet signalling blockade (CardioFibroMet). <i>9 months</i>	£50,000.00
TA/PPA/25/215064	Prof	T	Harris	Queen Mary, University of London	The development of a prototype device to deliver internal cardiac massage in cardiac arrest, improving survival. <i>9 months</i>	£50,000.00
TA/PPA/25/215112	Prof	A	Mathur	Queen Mary, University of London	From prototype to practice: evaluating the real-world translation of a hypertension digital twin. <i>9 months</i>	£45,380.00
TA/PPA/25/215037	Prof	A	McKillop	Ulster University	Repositioning omega-3 fatty acids for early prevention and treatment of dysglycaemia and cardiometabolic conditions. <i>9 months</i>	£35,008.00
TA/PPA/25/215102	Prof	A	Baker	University of Edinburgh	Defining clinical endpoints for human studies that use advanced therapies to prevent vein graft failure. <i>6 months</i>	£48,578.00
TA/PPA/25/215005	Dr	R	Nadarajah	University of Leeds	Development of the FIND-AF prototype to enable real-world piloting and licensing to potential customers. <i>6 months</i>	£30,000.00
TA/PPA/25/215006	Dr	O	Singh	University of Plymouth	Prototype flexible microneedle electrodes for long-term ECG monitoring. <i>8 months</i>	£29,876.00
TA/PPA/25/215049	Dr	K	MacLeod	University of Strathclyde	Proof of concept of novel bioabsorbable vascular scaffold for the treatment of congenital heart disease. <i>5 months</i>	£22,507.00
TA/PPA/25/215048	Dr	L	Holbrook	University of Surrey	Inorganic nanoparticles as a platform to deliver antiplatelet drugs and prevent thrombosis. <i>9 months</i>	£23,179.80

Project Grants

Listed alphabetically by institution

PG/26/12736	Prof	J	Crawley	Imperial College London	Delivering and reversing Super-TFPI – a novel anticoagulant therapy. <i>48 months</i>	£437,743.28
PG/26/12758	Dr	E	Duregotti	Imperial College London	Investigating the neuro-vascular interface in atherosclerosis. <i>36 months</i>	£247,289.19
PG/25/12509	Dr	C	Rhodes	Imperial College London	Identification of novel pulmonary hypertension therapeutic targets through genomic analyses. <i>24 months</i>	£338,609.31
PG/26/12701	Dr	J	Vermot	Imperial College London	Uncovering the mechanosensitive links between heartbeat and gene regulation in cardiac valve development. <i>36 months</i>	£362,711.32
PG/25/12669	Dr	D	Bromage	King's College London	Clonal haematopoiesis-driven neutrophil dysfunction in myocardial infarction. <i>36 months</i>	£310,833.50
PG/25/12490	Dr	J	Burgoyne	King's College London	Studying the role of FASN in the development of heart failure: alleviating metabolic and epigenetic dysfunction. <i>36 months</i>	£312,903.07
PG/25/12552	Prof	D	Perera	King's College London	Development and prospective application of a novel method to capture hospitalisation for heart failure and cardiovascular death from electronic health records utilising the NIHR REVIVED-BCIS2 trial. <i>36 months</i>	£315,139.92
PG/25/12683	Prof	D	Perera	King's College London	Impact of surgical versus percutaneous revascularisation on ischaemia reduction, scar burden and clinical outcomes in patients with severe left ventricular systolic dysfunction: a mechanistic sub-study of the BCIS-4 randomised control trial. <i>36 months</i>	£299,015.93
PG/25/12286	Prof	M	Shattock	King's College London	Intracellular Na elevation drives metabolic reprogramming, ROS production and pseudohypoxia in heart failure: a novel therapeutic target. <i>36 months</i>	£348,053.55
PG/25/12569	Dr	C	Derrick	Newcastle University	Validating hypoplastic left heart syndrome genetic variants using zebrafish. <i>36 months</i>	£272,298.76
PG/25/12397	Prof	G	Richardson	Newcastle University	CRISIS: Cardiac Remodelling and Injury via Senescent Immune cells. <i>36 months</i>	£271,196.06

PG/25/12590	Dr	A	Aubdool	Queen Mary, University of London	Defining the roles and therapeutic potential of C-type natriuretic peptide and neutral endopeptidase inhibition in aortic aneurysm associated with Marfan syndrome. <i>36 months</i>	£309,462.10
PG/26/12815	Dr	G	Czibik	Queen Mary, University of London	PHÆDRA: dysregulated phenylalanine catabolism drives cardiovascular complications of obstructive sleep apnoea by promoting adrenal catecholamine production. <i>36 months</i>	£325,885.64
PG/25/12583	Prof	P	Evans	Queen Mary, University of London	Does endothelial NOTCH4 drive atherosclerosis? <i>36 months</i>	£303,428.30
PG/25/12503	Dr	F	Lewis McDougall	Queen Mary, University of London	Targeting age-related metabolites to enhance hiPSC-cardiomyocyte differentiation. <i>36 months</i>	£347,341.01
PG/25/12428	Dr	G	Walls	Queen's University Belfast	Targeting the natriuretic peptide system in radiation cardio-oncology. <i>24 months</i>	£266,795.60
PG/25/12433	Dr	C	Watson	Queen's University Belfast	Collagen XIV in heart failure: investigating its biomarker potential and role in cardiac remodelling. <i>36 months</i>	£313,375.25
PG/25/12697	Prof	C	Ruhrberg	University College London	Novel mechanisms for arteriogenesis in peripheral artery disease. <i>36 months</i>	£349,851.85
PG/25/12405	Dr	C	Whyte	University of Aberdeen	Defining the role of fibrinolytic dysregulation in breast cancer associated thrombosis. <i>36 months</i>	£309,764.10
PG/25/12650	Dr	E	Slater	University of Birmingham	Bi-specific nanobodies to GPVI and $\alpha 2\beta 1$ as high affinity antiplatelet agents. <i>36 months</i>	£242,303.21
PG/25/12621	Prof	J	Hancox	University of Bristol	Can clinically reported gain-of-function hERG mutations disrupt early ventricular repolarisation? <i>36 months</i>	£273,557.00
PG/25/12593	Prof	A	Poole	University of Bristol	Comparative functional multi-omic analysis of platelet-derived exosomes in cardiac recovery after myocardial infarction. <i>36 months</i>	£313,254.88
PG/25/12346	Prof	M	Bennett	University of Cambridge	Identifying high-risk patients and plaques from optical coherence tomography (OCT) and biomechanics. <i>24 months</i>	£273,188.37
PG/26/12658	Dr	I	Mela	University of Cambridge	DNA origami nanostructures for targeted fibrinolytic delivery. <i>36 months</i>	£232,264.96

PG/25/12493	Prof	S	Ozanne	University of Cambridge	Cardiac extracellular vesicles as communicators between the heart and vasculature in offspring of control and obese pregnancy. <i>36 months</i>	£349,896.34
PG/25/12341	Prof	A	Baker	University of Edinburgh	Therapeutic and mechanistic assessment of extracellular vesicles derived from human pluripotent stem cell-derived endothelial cells. <i>30 months</i>	£331,218.63
PG/26/12823	Prof	M	Dweck	University of Edinburgh	Fibroblast activation in hypertrophic cardiomyopathy. <i>36 months</i>	£376,630.36
PG/25/12298	Dr	Z	Li	University of Edinburgh	Determining the prevalence and mechanisms of macrotroponin complex formation. <i>24 months</i>	£349,379.17
PG/25/12451	Prof	D	Newby	University of Edinburgh	The aortic stenosis and stroke paradox. <i>18 months</i>	£349,153.49
PG/25/12344	Prof	N	Basu	University of Glasgow	Mapping B-cell biology across the cardiovascular territories of giant cell arteritis: towards a new therapeutic approach. <i>24 months</i>	£235,624.00
PG/26/12660	Dr	E	MacDonald	University of Glasgow	Investigating Runx1 in arrhythmogenesis following myocardial infarction. <i>36 months</i>	£331,011.60
PG/25/12313	Prof	R	Myles	University of Glasgow	Understanding arrhythmia mechanism to improve risk stratification for life-threatening arrhythmia in the inherited long QT syndrome. <i>24 months</i>	£293,951.00
PG/25/12675	Dr	M	Pal	University of Kent	Chaperone-mediated assembly of axonemal dynein: effects on ciliary motility and cardiac health. <i>24 months</i>	£347,043.54
PG/25/12354	Dr	E	Dall Armellina	University of Leeds	Left ventricular myocardial remodelling in aortic stenosis: unravelling the structural changes in progressively worsening aortic stenosis using diffusion tensor imaging cardiac magnetic resonance. <i>36 months</i>	£299,204.41
PG/25/12417	Dr	R	Nadarajah	University of Leeds	Future innovations in novel detection of heart failure: a proof-of-concept study of an AI algorithm to increase early detection of heart failure. <i>34 months</i>	£339,691.04
PG/25/12399	Dr	R	Nadarajah	University of Leeds	Prediction of incident heart failure in patients with atrial fibrillation: bi-cohort national linked secondary and primary care records study. <i>15 months</i>	£99,950.12

PG/25/12624	Prof	H	Philippou	University of Leeds	Bypassing the intrinsic pathway: is plasma kallikrein activation of factor IX a shortcut to thrombosis? <i>36 months</i>	£298,827.16
PG/25/12504	Prof	J	Schneider	University of Leeds	Cardiac mitoDMRI: diffusion-weighted magnetic resonance imaging to non-invasively quantify mitochondrial content in the living heart. <i>24 months</i>	£336,397.61
PG/26/12564	Dr	R	Xu	University of Leeds	Affimers as allosteric FXIII-A modulators for the prevention of thrombosis. <i>36 months</i>	£294,918.31
PG/25/12532	Dr	G	Galli	University of Manchester	The impact of the foetal environment on cardiac channelopathy outcomes. <i>36 months</i>	£312,954.54
PG/25/12565	Dr	J	Penny	University of Manchester	Guess who? Unmasking the contribution of placenta-derived extracellular vesicles in the disruption of the blood brain barrier in preeclampsia. <i>36 months</i>	£322,697.98
PG/25/12396	Dr	C	Pinali	University of Manchester	Proteoglycans modulation of post myocardial infarction elasticity. <i>36 months</i>	£343,030.87
PG/25/12637	Prof	H	Shiels	University of Manchester	Old-age and air pollution: a cardiotoxic combination for arrhythmogenesis. <i>36 months</i>	£336,611.90
PG/26/12786	Dr	M	Zi	University of Manchester	Investigating the roles of peroxisomes under metabolic stress: is peroxisome dysfunction a contributor to heart failure development? <i>36 months</i>	£275,450.96
PG/25/12357	Prof	L	Heather	University of Oxford	Fumarate: an ischaemia-induced signalling metabolite, which is blunted by diabetes. <i>36 months</i>	£345,484.69
PG/26/12611	Prof	P	Leeson	University of Oxford	Long-term outcomes in the Physician-Optimised Postpartum Hypertension Treatment trial: the POP-HT five-year follow up. <i>24 months</i>	£338,534.98
PG/25/12656	Dr	D	Li	University of Oxford	Targeting NOS1AP cardiac activity in LQT1 using 3D human neurocardiac models. <i>36 months</i>	£339,555.83
PG/26/12693	Dr	I	McCracken	University of Oxford	Investigating the role of the API superfamily in endothelial differentiation. <i>24 months</i>	£170,354.34

PG/26/12634	Prof	N	Smart	University of Oxford	Epicardium-derived matricellular protein SPARC as a mediator of the switch from sprouting angiogenesis to arterialisation in the coronary vasculature. <i>36 months</i>	£305,052.51
PG/25/12338	Dr	O	Stone	University of Oxford	Investigating the function of a novel regulator of lymphatic vessel development. <i>36 months</i>	£336,932.11
PG/26/12837	Prof	P	Tammaro	University of Oxford	Uncovering new treatment targets for cardiac no-reflow: focus on the TMEM16A anion channel in pericytes. <i>36 months</i>	£339,474.85
PG/25/12527	Dr	M	Weinberger	University of Oxford	Single cell profiling of cardiac repair in the adult spiny mouse. <i>36 months</i>	£342,496.26
PG/25/12489	Prof	M	Zaccolo	University of Oxford	PDE2A2 and regulation of cardiac myocyte energy metabolism. <i>24 months</i>	£300,668.13
PG/25/12308	Dr	V	Ridger	University of Sheffield	Modulation of vascular smooth muscle cell phenotype and function in atherosclerosis by neutrophil microvesicles. <i>36 months</i>	£349,571.00
PG/25/12630	Dr	I	Smyrnias	University of Surrey	Understanding the role of a novel signalling complex in the regulation of mitochondrial quality control pathways in stressed cardiomyocytes. <i>36 months</i>	£338,287.99



bhf.org.uk

© British Heart Foundation 2026, a registered charity in
England and Wales (225971) and Scotland (SC039426)